At SNOS Pharma, our focus is on eliminating health and care inequalities, improving access to cutting-edge treatments, and enhancing the overall quality of life. We are driven by a commitment to reduce both mortality and morbidity rates, not only in the UK but on a global scale. Cigarettes and vapes, due to their widespread use, pose serious threats to public health. Cigarettes are well-known to cause a range of life-threatening conditions, including lung cancer, heart disease, and chronic respiratory disorders.

Vaping, while often promoted as a safer alternative, is not without substantial risks. Emerging research highlights the harmful effects of chemicals in vapes and e-cigarettes, leading to lung damage, cancer, and long-term health issues. Both smoking and vaping start the cycle of Nicotine addiction, with millions of lives at risk due to tar, carcinogens, and other harmful compounds that are inhaled into the lungs.

In response to this urgent need for a safer solution, SNOS Pharma has created something truly revolutionary – Nicotine Oral Strips. These strips are designed to assist individuals in quitting smoking, offering a safer, innovative alternative that satisfies Nicotine cravings without the harmful byproducts associated with smoking or vaping.

SNOS is a cornerstone of our vision to safeguard lives, address health inequalities, and empower people on their journey towards a healthier, smoke-free future.

Our goal extends beyond managing Nicotine addiction; we endeavour to reduce the global burden of smoking-related diseases, ultimately improving and saving millions of lives worldwide.